Summary by Moomoo AI
On March 15, 2024, bluebird bio, Inc. entered into a significant financial agreement with several banks and financial institutions, with Hercules Capital, Inc. serving as the administrative and collateral agent. The Loan and Security Agreement (LSA) provides bluebird bio with a secured term loan facility totaling up to $175 million. The initial tranche of $75 million was funded at closing, with additional tranches available upon meeting specific milestones related to the company's LYFGENIA patients and financial performance. The term loans carry an interest rate based on the Prime Rate plus a margin or a fixed rate, with interest payable monthly and principal repayments starting after an interest-only period, maturing on April 1, 2029. Prepayment premiums apply if the loans are repaid early, and the...Show More